uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Beta-MSH inhibits brain inflammation via MC(3)/(4) receptors and impaired NF-kappaB signaling
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences, Pharmaceutical Pharmacology. (Proteochemometric group)
Show others and affiliations
2005 (English)In: Journal of Neuroimmunology, ISSN 0165-5728, E-ISSN 1872-8421, Vol. 169, no 1-2, 13-19 p.Article in journal (Refereed) Published
Abstract [en]

The anti-inflammatory effects of melanocortin peptides have been demonstrated in different inflammation models. This is the first report describing the molecular mechanisms for the beta-MSH-induced suppression of bacterial lipopolisaccharide (LPS)-caused brain inflammation. We found that beta-MSH suppresses LPS-induced nuclear translocation of the transcription factor NF-kappaB, and inhibits the expression of inducible nitric oxide synthase, and the following nitric oxide overproduction in the brain, in vivo. Moreover, administering the preferentially MC(4) receptor selective antagonist HS014 blocked completely these effects, suggesting a tentative MC(4) receptor mediated mechanism of action for the beta-MSH. However, as HS014 shows quite low selectivity vis-à-vis the MC(3) receptor, a role for the MC(3) receptor cannot be excluded. In conclusion, our results show that beta-MSH is capable of inhibiting brain inflammation via activation of melanocortin receptors, of the subtypes 4 and/or 3.

Place, publisher, year, edition, pages
2005. Vol. 169, no 1-2, 13-19 p.
Keyword [en]
Animals, Brain Chemistry/drug effects, Comparative Study, Disease Models; Animal, Dose-Response Relationship; Drug, Drug Interactions, Electron Spin Resonance Spectroscopy/methods, Electrophoretic Mobility Shift Assay/methods, Encephalitis/chemically induced/*drug therapy, Hormones/*therapeutic use, Immunochemistry/methods, Lipopolysaccharides, Male, Mice, Mice; Inbred ICR, NF-kappa B/*metabolism, Nitric Oxide/metabolism, Nitric Oxide Synthase Type II/metabolism, Peptides; Cyclic/pharmacology, Receptor; Melanocortin; Type 3/*physiology, Receptor; Melanocortin; Type 4/*physiology, Research Support; Non-U.S. Gov't, Signal Transduction/*physiology, beta-MSH/*therapeutic use
National Category
Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:uu:diva-104276DOI: 10.1016/j.jneuroim.2005.07.024PubMedID: 16154641OAI: oai:DiVA.org:uu-104276DiVA: diva2:219587
Available from: 2009-05-28 Created: 2009-05-28 Last updated: 2017-12-13Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
By organisation
Pharmaceutical Pharmacology
In the same journal
Journal of Neuroimmunology
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 444 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf